Short Interest in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Grows By 48.6%

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) saw a large growth in short interest during the month of February. As of February 27th, there was short interest totaling 37,152 shares, a growth of 48.6% from the February 12th total of 24,997 shares. Based on an average daily trading volume, of 810,829 shares, the days-to-cover ratio is presently 0.0 days. Currently, 5.2% of the company’s shares are sold short. Currently, 5.2% of the company’s shares are sold short. Based on an average daily trading volume, of 810,829 shares, the days-to-cover ratio is presently 0.0 days.

Bluejay Diagnostics Price Performance

BJDX opened at $1.90 on Friday. Bluejay Diagnostics has a one year low of $1.70 and a one year high of $40.80. The business has a 50 day simple moving average of $2.61 and a two-hundred day simple moving average of $4.98. The firm has a market capitalization of $1.84 million, a price-to-earnings ratio of 0.00 and a beta of 0.72.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its quarterly earnings data on Friday, March 6th. The company reported $3.23 earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Bluejay Diagnostics presently has a consensus rating of “Sell”.

Institutional Trading of Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics at the end of the most recent quarter. Institutional investors and hedge funds own 18.47% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.